DK3777855T3 - Fremgangsmåder til behandling af fibrotiske sygdomme - Google Patents

Fremgangsmåder til behandling af fibrotiske sygdomme Download PDF

Info

Publication number
DK3777855T3
DK3777855T3 DK20194458.4T DK20194458T DK3777855T3 DK 3777855 T3 DK3777855 T3 DK 3777855T3 DK 20194458 T DK20194458 T DK 20194458T DK 3777855 T3 DK3777855 T3 DK 3777855T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
fibrotic diseases
fibrotic
diseases
Prior art date
Application number
DK20194458.4T
Other languages
English (en)
Inventor
Robert Walczak
Carole Belanger
Pierre Daubersies
Philippe Delataille
Raphaël Darteil
Emilie Negro
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Application granted granted Critical
Publication of DK3777855T3 publication Critical patent/DK3777855T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DK20194458.4T 2016-04-11 2017-03-13 Fremgangsmåder til behandling af fibrotiske sygdomme DK3777855T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11
EP17710285.2A EP3442580B1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (1)

Publication Number Publication Date
DK3777855T3 true DK3777855T3 (da) 2023-01-09

Family

ID=55755536

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17710285.2T DK3442580T3 (da) 2016-04-11 2017-03-13 Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK20194458.4T DK3777855T3 (da) 2016-04-11 2017-03-13 Fremgangsmåder til behandling af fibrotiske sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17710285.2T DK3442580T3 (da) 2016-04-11 2017-03-13 Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme

Country Status (23)

Country Link
US (7) US20170290812A1 (da)
EP (3) EP3777854B1 (da)
JP (1) JP6894923B2 (da)
KR (1) KR102431257B1 (da)
CN (1) CN109069648B (da)
AU (1) AU2017249602B2 (da)
DK (2) DK3442580T3 (da)
EA (2) EA202191466A1 (da)
ES (3) ES2839453T3 (da)
HR (1) HRP20201954T1 (da)
HU (2) HUE052886T2 (da)
IL (1) IL262052B (da)
LT (1) LT3442580T (da)
MD (1) MD3442580T2 (da)
MX (1) MX384261B (da)
MY (1) MY195437A (da)
PH (1) PH12018502142B1 (da)
PL (1) PL3442580T3 (da)
PT (2) PT3442580T (da)
SG (2) SG11201808402RA (da)
SI (1) SI3442580T1 (da)
WO (1) WO2017178172A1 (da)
ZA (1) ZA201807389B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3442580T1 (sl) 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
SG11201907673YA (en) 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
BR112019019519A2 (pt) * 2017-03-21 2020-04-22 Novalead Pharma Inc agente terapêutico para a inibição de fosfodiesterase e seus distúrbios relacionados
US11547699B2 (en) 2017-11-17 2023-01-10 Hubert Köster [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
WO2020208205A1 (en) 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
EP3952869A1 (en) 2019-04-12 2022-02-16 Genfit Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
JP7741800B2 (ja) 2019-10-28 2025-09-18 ジェンフィット 抗酸化性質を有する併用療法
CN113398125B (zh) * 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
US20240000754A1 (en) * 2020-11-17 2024-01-04 Genfit Methods of treatment of liver failure
CN116507343A (zh) * 2020-11-17 2023-07-28 基恩菲特公司 治疗肝衰竭的方法
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
KR20240006588A (ko) * 2021-05-11 2024-01-15 장피트 패혈증의 치료에서의 니타족사나이드
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用
CN119907669A (zh) * 2022-10-04 2025-04-29 基恩菲特公司 用于治疗肝损伤的硝唑尼特
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
WO2025063816A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물
CN117838690B (zh) * 2023-10-09 2024-09-13 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2002051442A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
US7973169B2 (en) 2003-09-06 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20100056505A1 (en) 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
JP2009524677A (ja) 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
WO2009039248A2 (en) 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
KR101840479B1 (ko) 2009-11-16 2018-03-20 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
CN103269593A (zh) 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
WO2016210247A1 (en) 2015-06-24 2016-12-29 Duke University New methods of use for an anti-diarrhea agent
IL262186B2 (en) 2016-04-11 2023-10-01 Genfit Synergistic combinations of nitazoxanide (ntz) compounds and statins
US20170290814A1 (en) 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
SI3442580T1 (sl) 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni

Also Published As

Publication number Publication date
JP2019513761A (ja) 2019-05-30
CN109069648A (zh) 2018-12-21
HRP20201954T1 (hr) 2021-02-05
EP3777855B1 (en) 2022-10-19
PL3442580T3 (pl) 2021-04-06
MY195437A (en) 2023-01-20
PT3777855T (pt) 2023-01-10
IL262052B (en) 2021-12-01
US10130613B2 (en) 2018-11-20
EP3442580B1 (en) 2020-09-23
CN109069648B (zh) 2022-01-14
US20180092884A1 (en) 2018-04-05
EP3777855A1 (en) 2021-02-17
MX384261B (es) 2025-03-14
PH12018502142A1 (en) 2019-07-29
BR112018069684A2 (pt) 2019-01-29
US20170290812A1 (en) 2017-10-12
US20200316031A1 (en) 2020-10-08
NZ746668A (en) 2024-12-20
US10117855B2 (en) 2018-11-06
US20180092885A1 (en) 2018-04-05
WO2017178172A1 (en) 2017-10-19
MX2018012287A (es) 2019-02-07
PH12018502142B1 (en) 2023-08-11
EP3777854A1 (en) 2021-02-17
PT3442580T (pt) 2020-12-23
ES2928408T3 (es) 2022-11-17
HUE060671T2 (hu) 2023-04-28
AU2017249602B2 (en) 2022-06-16
SG11201808402RA (en) 2018-10-30
EA202191466A1 (ru) 2021-12-31
US20180092886A1 (en) 2018-04-05
CA3019399A1 (en) 2017-10-19
MD3442580T2 (ro) 2021-04-30
SG10202004425XA (en) 2020-06-29
IL262052A (en) 2018-11-29
KR20180129934A (ko) 2018-12-05
EA201892298A1 (ru) 2019-04-30
DK3442580T3 (da) 2020-12-21
AU2017249602A1 (en) 2018-10-18
HUE052886T2 (hu) 2021-05-28
KR102431257B1 (ko) 2022-08-10
SI3442580T1 (sl) 2021-01-29
US10130612B2 (en) 2018-11-20
US10117856B2 (en) 2018-11-06
LT3442580T (lt) 2020-12-28
JP6894923B2 (ja) 2021-06-30
EP3777854B1 (en) 2022-07-20
EP3442580A1 (en) 2019-02-20
US11103484B2 (en) 2021-08-31
ES2839453T3 (es) 2021-07-05
ZA201807389B (en) 2020-01-29
ES2935185T3 (es) 2023-03-02
US20190000813A1 (en) 2019-01-03
US20180085354A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
IL272851A (en) Methods of using dipivefrin
PL3288581T3 (pl) Sposób leczenia nowotworu
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3171928T3 (da) Stimulationsmønstre til behandling af tørt øje
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3458052T3 (da) Kombinationsbehandling af cancer
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
IL257764B (en) Methods for treatment of diseases
DK3307267T3 (da) Behandling af multipel sklerose
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
PL3393468T3 (pl) Metody leczenia niedoboru odporności
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3374495T3 (da) Forbedrede fremgangsmåder til vævsfremstilling
DK3209295T4 (da) Fremgangsmåder til behandling af øjenlidelser